The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET).
James C. Yao
Consultant or Advisory Role - Endo Pharmaceuticals; Ipsen; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Genentech; Novartis
John D. Hainsworth
No relevant relationships to disclose
Edward M. Wolin
Consultant or Advisory Role - Novartis
Marianne E. Pavel
Consultant or Advisory Role - Novartis
Eric Baudin
Honoraria - Novartis
David Gross
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Philippe Ruszniewski
Consultant or Advisory Role - Ipsen; Novartis; Pfizer
Honoraria - Ipsen; Novartis; Pfizer
Research Funding - Ipsen; Novartis; Pfizer
Paola Tomassetti
No relevant relationships to disclose
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Stephen Saletan
Employment or Leadership Position - Novartis
Judith Klimovsky
Employment or Leadership Position - Novartis
Stock Ownership - Novartis